Chemo-Free combo shows promise for tough breast cancer
NCT ID NCT03650894
First seen Apr 19, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) to control metastatic HER2-negative breast cancer without using chemotherapy. The goal is to see if this approach can shrink tumors or keep them stable for at least 24 weeks. The trial involves 30 adults with advanced breast cancer that cannot be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Providence Oncology & Hematology Care Clinic - Eastside
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.